Loading…
Loading…
KOAN does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for KOAN and 80,000+ other tickers.
See exactly how KOAN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for KOAN and 80,000+ other tickers.
APOLLO BioWellness Inc. focuses its efforts on researching, formulating, and bringing to market products designed for human health within the regenerative medicine sector. A significant part of its operations involves the commercialization of licensed, naturally derived compounds currently awaiting patent approval, which are specifically engineered to boost an individual's innate capacity to mobilize adult stem cells from their own bone marrow. Additionally, the firm possesses the marketing rights for an all-natural, two-pronged dietary supplement crafted to help regulate hunger by engaging…
GN Store Nord (OTCMKTS:GNNDY - Get Free Report) and Resonate Blends (OTCMKTS:KOAN - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk. Volatility and Risk GN Store Nord has
North Bergen, New Jersey--(Newsfile Corp. - April 8, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company" or "Apollo"), in conjunction with the final due diligence being reviewed by MedwellAI, Inc. (OTCQB: MWAI) to acquire Apollo and its subsidiaries including Evolutionary Biologics, Inc. ("Evo Bio"), (the "Transaction"), MWAI has reserved a Preferred Series B class of stock for the share exchanged and assumption of certain liabilities of Apollo. Negotiations are ongoing with certain secured creditors and debtholders of the Company that need to be resolved prior to closing the transaction.
North Bergen, New Jersey--(Newsfile Corp. - February 10, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company) is pleased to announce the signing of a Letter of Intent ("LOI") to create a vertically integrated health, wellness and longevity platform. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10533/283349_a912020384f54aed_001full.jpg New MedWell Ai, Inc (OTCQB: MWAI) will be organized across three core divisions: (1) national pharma distribution and telemed platform, (2) nationwide portfolio of premium surgical and cosmetic centers and men's healthcare franchise brand and (3) advanced biologics and product innovation group.
North Bergen, New Jersey--(Newsfile Corp. - February 6, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company), announces that the 'Exclusive Distribution Agreement' dated July 1, 2025, between Evolutionary Biologics (a wholly owned subsidiary of Apollo Biowellness) and Revive Regenerative, Inc. ("Revive") has been "terminated for cause" by Evolutionary Biologics, for reasons already disclosed to Revive Regenerative, Inc. and is no longer in effect. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10533/282940_dec73984c4625bd8_001full.jpg The Company will resume management of the distribution and marketing of the Evolutionary Biologics Brands and Products through its own efforts and non-exclusive distribution agreements, while pursuing other opportunities.
North Bergen, New Jersey--(Newsfile Corp. - January 7, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), announces that the Letter of Intent between the Company and Revive Regenerative, Inc., dated September 12, 2025, (the "LOI") has expired and it no longer in effect. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10533/279422_3bd62a33d4b12bbb_001full.jpg The LOI contained a proposed closing date of October 31, 2025, unless extension was provided in writing by the parties.